ReviewCurrent opinion in HIV and AIDS2011
Targeting viral reservoirs: ability of antiretroviral therapy to stop viral replication.
Review in Current opinion in HIV and AIDS, 2011. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 17 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
17 citing papers in PubMed, 29 citations in OpenAlex.
- Modelling HIV-1 2-LTR dynamics following raltegravir intensification.Journal of the Royal Society, Interface · 2013Trial
- Therapeutic vaccination expands and improves the function of the HIV-specific memory T-cell repertoire.The Journal of infectious diseases · 2013Trial
- Review
- Modeling the role of macrophages in HIV persistence during antiretroviral therapy.Journal of mathematical biology · 2020Article
- Experiment Design for Early Molecular Events in HIV Infection.Proceedings of the ... American Control Conference. American Control Conference · 2017Article
- The role of HIV integration in viral persistence: no more whistling past the proviral graveyard.The Journal of clinical investigation · 2016Review
- Targeting the Brain Reservoirs: Toward an HIV Cure.Frontiers in immunology · 2016Review
- Single-copy quantification of HIV-1 in clinical samples.Methods in molecular biology (Clifton, N.J.) · 2014Article
- Latent HIV-1 can be reactivated by cellular superinfection in a Tat-dependent manner, which can lead to the emergence of multidrug-resistant recombinant viruses.Journal of virology · 2013Article
- Cell-associated HIV RNA: a dynamic biomarker of viral persistence.Retrovirology · 2013Review
- Article
- HIV pathogenesis: dynamics and genetics of viral populations and infected cells.Cold Spring Harbor perspectives in medicine · 2013Article
- Eliminating the HIV reservoir.Current HIV/AIDS reports · 2012Review
- Achieving a cure for HIV infection: do we have reasons to be optimistic?The Journal of antimicrobial chemotherapy · 2012Review
- Generation of HIV latency in humanized BLT mice.Journal of virology · 2012Article
- Clinical management of HIV drug resistance.Viruses · 2011Review
- Quantitative analysis of viral persistence and transient viral load rebound from HIV clinical data.Annual International Conference of the IEEE Engineering in Medicine and Biology Society. IEEE Engineering in Medicine and Biology Society. Annual International Conference · 2011Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
1 author at 1 institution in 1 country.
Funding
Abstract
purpose of reviewHIV infection is controlled but not cured by combination antiretroviral therapy. HIV may persist for a number of reasons, including ongoing cycles of HIV infection or viral persistence as latent, or HIV replication in long-lived cells containing HIV proviruses. Therapeutic consequences of these alternative mechanisms are significant and distinct. If ongoing replication remains during current antiretroviral therapy, then improvements in potency will be useful in eradication strategies. Alternatively, long-lived cells with integrated proviruses will not be affected by improvements in therapy directed against active infection, and new strategies will be necessary for HIV eradication. Technologic advances have made it possible to carry out a series of drug intensification protocols in well suppressed patients; these and other analyses for HIV replication have been useful to elucidate the nature of HIV persistence on therapy. RECENT
findingsA number of clinical studies intensifying antiretroviral therapy carried out in the last several years have yielded new findings regarding the ability to detect the presence of ongoing replication. Decreases in persistent viremia have not been consistently detected in individuals on potent combination antiretroviral therapy. Evidence for persistent replication has been reported in patients using sensitive assays of cell-associated HIV. SUMMARY: HIV viremia persists despite combination antiretroviral therapy. Antiretroviral drug intensification does not lower the level of HIV measured in plasma, suggesting current therapy arrests active virus replication. HIV eradication will most likely require therapy in addition to potent antiretroviral therapy.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.